|TGF-β Inhibitors||Discovery||Preclinical||Phase I||Phase II||Phase III|
|High-Grade Glioma (intratumoral)|
|Malignant Melanoma (intravenous)|
|Pancreatic Cancer (intravenous)|
|Solid Tumors (intravenous)|
|Solid Tumors (intratumoral)|
Antisense Pharma develops innovative drugs for targeted therapy of malignant tumors. The conceptual therapeutic approach is to help the body’s own immune system to recognize tumor cells and successfully destroy them.
Trabedersen is our most advanced antisense drug that targets the protein “transforming growth factor beta 2” (TGF-β2), a very important component of the tumor´s defense against the immune system. Trabedersen has been evaluated in several clinical studies. First clinical signs of anti-tumor activity with encouraging survival outcome were observed in these studies, which is why further studies in cancer patients are being planned.
Other novel proprietary next generation antisense oligonucleotide candidates, which target different TGF-β isoforms (1 to 3; pan) to treat high unmet medical need cancer indications, are in development. These potent compounds have shown impressive anti-TGF-β activity in preclinical evaluations.